<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172444</url>
  </required_header>
  <id_info>
    <org_study_id>MESA-ULP3125</org_study_id>
    <nct_id>NCT01172444</nct_id>
  </id_info>
  <brief_title>Clinical Trial With Mesalamine 1g Suppositories</brief_title>
  <official_title>AN INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ESTABLISH THERAPEUTIC EQUIVALENCE OF 1000 mg MESALAMINE RECTAL SUPPOSITORIES AND CANASA® RECTAL SUPPOSITORIES (1000 mg MESALAMINE, USP) IN THE TREATMENT OF MILD TO MODERATE ULCERATIVE PROCTITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Establish&#xD;
      Therapeutic Equivalence of 1000 mg Mesalamine Rectal Suppositories and Canasa® Rectal&#xD;
      Suppositories (1000 mg Mesalamine, USP) in the Treatment of Mild to Moderate Ulcerative&#xD;
      Proctitis will be conducted in 533 patient with a estimated duration of 18months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment difficulties&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DAI Score</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Mean difference in the DAI score between Baseline and the Final Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAI Score, Improvement, Remission &amp; Histological Disease Activity Score</measure>
    <time_frame>3 and 6 Weeks</time_frame>
    <description>The mean difference in the DAI score and each of the individual DAI parameters between Baseline, Interim and Final Visits&#xD;
Proportion of patients achieving an &quot;improvement&quot;, defined as a ≥3 point improvement in overall DAI score and the proportion of patients achieving a &quot;remission&quot;, where &quot;remission&quot; is defined as a DAI score of 0-1 at the Interim and Final Visit.&#xD;
The mean difference in the histological disease activity score between baseline and the Final Visit</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Proctitis</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sandoz Mesalamine 1 g Suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Canasa 1 g Suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sandoz 1 g Placebo Suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine</intervention_name>
    <description>Supporitory, Once Daily, Per Rectal for 6 Weeks</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canasa</intervention_name>
    <description>Suppository, Once Daily, Per Rectal for 6 Weeks</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suppository, Once Daily, Per Rectal for 6 Weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Adults, male and female, 18 to 65 years of age 2. Active, mild to moderate UP, with&#xD;
        disease activity not to exceed 15 cm beyond the anal verge: the upper disease boundary will&#xD;
        be confirmed by flexible sigmoidoscopy/colonoscopy performed within 14 days of the Baseline&#xD;
        Visit 3. Newly diagnosed or newly relapsed UP, where newly relapsed UP is defined as UP&#xD;
        that has relapsed within less than and equal to 6 weeks prior to the Baseline Visit 4. A&#xD;
        Disease Activity Index (DAI) score greater than or equal to 4 and less than or equal to 10&#xD;
        at the Baseline Visit; the DAI must include a Physician's Global Assessment (PGA) sub-score&#xD;
        of less than or equal to 2, a rectal bleeding sub-score of greater than or equal to 1 and a&#xD;
        mucosal appearance sub-score of greater than or equal to 1 5. Histological confirmation of&#xD;
        UP with a Histological Disease Activity Score &gt; or equal to 1 for the biopsy taken from the&#xD;
        most severe area of disease during the flexible sigmoidoscopy/colonoscopy performed within&#xD;
        14 days of the Baseline Visit 6. For female patients of child-bearing potential, a negative&#xD;
        serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the&#xD;
        Baseline Visit; all female patients will be considered of child-bearing potential unless&#xD;
        they are post-menopausal for at least one year or have been surgically sterilized&#xD;
        (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) 7. Female patients of&#xD;
        childbearing potential must be practicing one of the following methods of birth control and&#xD;
        must agree to continue with regimen throughout the study: hormonal methods such as oral,&#xD;
        implantable, injectable, or transdermal contraceptives for a minimum of one full cycle&#xD;
        (based on the patient's usual menstrual cycle period) before investigational product&#xD;
        administration; total abstinence from sexual intercourse (since the last menses before&#xD;
        investigational product administration); intrauterine device; double barrier method&#xD;
        (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream); Male&#xD;
        patients must also agree to use acceptable methods of birth control with their female&#xD;
        partners, and this may include use of a male condom plus spermicide. 8. Ability to give&#xD;
        written informed consent 9. Ability and willingness to comply with study requirements,&#xD;
        including dosing procedures, diary completion, and study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Known history of allergic reaction or clinically significant intolerance to aspirin or&#xD;
        salicylate derivatives (including mesalamine) or non-active ingredients of the&#xD;
        investigational product 2. Onset of UP relapse &gt;6 weeks prior to the Baseline Visit for&#xD;
        patients experiencing a relapse of their UP (i.e., patients who are not newly diagnosed) 3.&#xD;
        Severe UP as defined by a DAI score of greater than or equal to 11 or a PGA sub-score of 3&#xD;
        4. Histological Disease Activity Score &gt; or equal to 1 for the biopsy taken from the normal&#xD;
        tissue above the disease margin during the flexible sigmoidoscopy/colonoscopy performed&#xD;
        within 14 days of the Baseline Visit 5. UP with disease involvement greater than 15 cm&#xD;
        beyond the anal verge as confirmed on flexible sigmoidoscopy/colonoscopy 6. Prior&#xD;
        unsuccessful treatment of active UP or active ulcerative colitis with rectally administered&#xD;
        mesalamine preparations of any strength 7. Any prior treatment of UP or ulcerative colitis&#xD;
        with any oral 5-aminosalicylic acid product if used at &gt;2 g/day, regardless of treatment&#xD;
        outcome 8. Use of local, rectally administered therapies for UP or ulcerative colitis&#xD;
        (e.g., suppositories or enemas containing mesalamine, etc.) within 30 days of the Baseline&#xD;
        Visit 9. Use of any of the following medications: - Biological therapies (e.g., infliximab)&#xD;
        within 90 days of the Baseline Visit - Immunosuppressive/immunomodulating (e.g.,&#xD;
        azathioprine) medications within 90 days of the Baseline Visit - Oral, intravenous,&#xD;
        intramuscular, or rectally administered corticosteroids within 30 days of the Baseline&#xD;
        Visit; the use of intranasal and/or inhaled corticosteroids is permitted - Oral&#xD;
        5-aminosalicylic acid products within 7 days of the Baseline Visit, if used at &amp; less than&#xD;
        or equal to 2 g/day - Oral, intravenous, or intramuscular antibiotics within 7 days of the&#xD;
        Baseline Visit - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within 7 days of the&#xD;
        Baseline Visit; low-dose aspirin (less than or equal to 325 mg/day) taken for&#xD;
        cardio-protective reasons is permitted - Antidiarrheals, antispasmodics, and iron therapy&#xD;
        within 7 days of the Baseline Visit - Transdermal nicotine products within 7 days of the&#xD;
        Baseline Visit 10. A change in regimen (i.e., dosage or frequency of use) of permitted&#xD;
        medications within 30 days of the Baseline Visit, or any plans to change the regimen during&#xD;
        the course of this study 11. Use or treatment with an investigational drug, therapy, or&#xD;
        device within 30 days of the Baseline Visit 12. A planned change in tobacco usage (e.g.,&#xD;
        smoking, oral tobacco) during the study 13. Female patients who are pregnant, planning a&#xD;
        pregnancy, or who are breastfeeding 14. Diseases interfering with the DAI assessment,&#xD;
        including but not limited to, hemorrhoids and anal fissures 15. History of Crohn Disease,&#xD;
        short bowel syndrome, or bowel surgery (except appendectomy), or active peptic ulcer 16. A&#xD;
        positive stool culture for enteric pathogens (Salmonella, Shigella, Yersinia,&#xD;
        Campylobacter, Vibrio, E. coli O157/H7), detection of Clostridium difficile toxin through&#xD;
        immunoassay, or enteric parasites and their ova (including Giardia, Cryptosporidium, and&#xD;
        Entamoeba histolytica) on routine microscopy at the Screening Visit 17. Significant&#xD;
        impairment of renal or hepatic function, as defined by any of the following: - Creatinine&#xD;
        &gt;1.5 x Upper Limit Normal (ULN) - Alanine Amino Transferase (ALT) &gt;2.5 x ULN - Aspartate&#xD;
        Amino Transferase (AST) &gt;2.5 x ULN 18. Serologic positivity for the Hepatitis B virus&#xD;
        (HBV), the Hepatitis C virus (HCV), the Human Immunodeficiency Virus (HIV), or Treponema&#xD;
        pallidum (the causative agent of syphilis) 19. Known history of idiopathic / chronic&#xD;
        pancreatitis 20. History of active drug or alcohol abuse within the past year, or physical&#xD;
        examination findings indicating the same 21. Current clinically significant urinary tract&#xD;
        obstruction 22. History of coagulation disorders, including those requiring treatment with&#xD;
        anticoagulant drugs (except for aspirin taken at ≤325 mg/day for cardio-protective reasons&#xD;
        23. Current active malignancy or history of malignancy within the past five years, except&#xD;
        for cervical carcinoma in situ, squamous or basal cell carcinoma of the skin that has been&#xD;
        surgically removed, or prostate cancer that is being managed by watchful waiting&#xD;
        (observation alone) 24. History of pelvic irradiation 25. Any other clinically significant&#xD;
        abnormal medical condition that in the Investigators judgment would put the patient at&#xD;
        increased risk of illness or injury, would interfere with study participation or would&#xD;
        interfere with the evaluation or quality of the data 26. Inability or unwillingness to&#xD;
        understand and comply with the requirements of the protocol for any reason, including&#xD;
        dosing procedures and visit requirements 27. Previous randomization in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kamineni Hospitals, 4-1-1227, King Koti Road, Abids</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Instiute of Medical Sciences, Department of Gastroenterology</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andhra Hospitals</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagarjuna Hospitals Limited</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manikya Institute of Gastroenterology and Hepatology, MVV Chambers,203,204</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Digestive and Liver Diseases</name>
      <address>
        <city>Guwahati</city>
        <state>Assam</state>
        <zip>781006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Liver &amp; Gastroenterology Centre, E-5/24, Opp Arera Petrol Pump</name>
      <address>
        <city>Arera Colony</city>
        <state>Bhopal</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indira Gandhi Institute of Medical Sciences</name>
      <address>
        <city>Sheikhpura, Patna</city>
        <state>Bihar</state>
        <zip>800014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Sheth V. S. General Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ratandeep Surgical Hospital &amp; Endoscopy Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bhatnagar's Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital International Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>382428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Care Clinic</name>
      <address>
        <city>Rajkot</city>
        <state>Gujarat</state>
        <zip>360001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Care</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gokula Metropolis Clinical Research Center, M.S.Ramaiah Memorial Hospital, New BEL Road, MSRIT Post</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PVS Memorial Hospital</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sree Gokulam Medical College and Research Foundation</name>
      <address>
        <city>Thiruvanathapuram</city>
        <state>Kerala</state>
        <zip>695607</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gut- N-Hepa Care</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEM Hospital &amp; Research Centre, Department of Surgery</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midas Institute of Gastroenterology</name>
      <address>
        <city>Ramdaspeth</city>
        <state>Nagpur</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroentrology, Postgraduate Institute of Medical Education &amp; Research</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Nijhawan's Clinic</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharma Gastroenterology Centre</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302021</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kala Endoscopy &amp; Liver Clinic</name>
      <address>
        <city>Jodhpur</city>
        <state>Rajasthan</state>
        <zip>342001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospitals, Lake View Road, K. K. Nagar</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajanta Hospital and IVF Center 765, ABC Complex , Kanpur Road</name>
      <address>
        <city>Alambagh, Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S.M Medical University, Department of Surgical Gastroenterology, New Surgical Block (NSB)</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Gastroenterology, Fortis Hospital, B-22, Sector-62</name>
      <address>
        <city>Noida</city>
        <state>Uttar Pradesh</state>
        <zip>20130</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samvedna Hospital, B 27/88G, New Colony</name>
      <address>
        <city>Ravindrapuri</city>
        <state>Varanasi</state>
        <zip>221005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anand Multispeciality Hospitals Pvt Ltd, White house, Opp Rajasthan Hospital,Shahibaug</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leads Medical Center, First Floor, Ozone Complex</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Gastroenterology &amp; Hepatology, Deccan College of Medical Sciences,Owaisi Hospital &amp; Research Centre</name>
      <address>
        <city>Hyderabad</city>
        <zip>500058</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAI Speciality Care Centre</name>
      <address>
        <city>Jaipur</city>
        <zip>342019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Digestive and Liver Diseases, IPGME&amp;R</name>
      <address>
        <city>Kolkata</city>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Endoscopy Center</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Consultant-Gastroenterology and Hepatology, Indraprastha Apollo Hospitals</name>
      <address>
        <city>New Delhi</city>
        <zip>110044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences Ltd</name>
      <address>
        <city>Secunderabad</city>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Clinic</name>
      <address>
        <city>Surat</city>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild to Moderate Ulcerative Proctitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proctitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

